Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% rem
How this was made
The 30-second read
Why it matters
The most tradable elements are the newly described clinical biopsy and serum biomarker outcomes for PBGENE-HBV, plus operational updates for PBGENE-DMD enrollment and the company’s stated cash balance supporting milestones through 2028.
Market read
DTIL’s 8-K adds concrete clinical proof points for HBV cccDNA elimination and updates trial recruitment and cash runway, which can shift near-term biotech sentiment and positioning ahead of year-end milestones.
What to watch
The filing highlights LNP-related hypotension mitigation and steroid use; investors may discount efficacy claims until larger cohorts confirm tolerability and consistent biomarker kinetics.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and a business update for Precision BioSciences’ in vivo gene editing programs.
Ticker impact
Precision BioSciences reports Q2 2026 results and new ELIMINATE-B biopsy evidence of direct cccDNA elimination plus ongoing FUNCTION-DMD recruitment.
Likely positive near-term sentiment for DTIL on perceived de-risking of HBV cure mechanism, with follow-through tied to year-end 2026 updates.
The filing is a fresh 8-K with specific clinical findings (biopsy cccDNA reduction, pgRNA undetectability durability) and operational milestones (new sites, recruiting cohorts), which can re-rate probability of success. However, it is still early-stage and the article does not provide valuation-changing financial guidance beyond cash balance.
Market effects
Reinforces investor focus on in vivo gene editing platforms and HBV cure read-through, potentially supporting sentiment for adjacent gene-editing names.
Limited direct regional impact; primarily US biotech sentiment.
EASL congress-linked HBV data and multi-country trial enrollment can influence global clinical-gene-editing risk appetite.
Counterpoint
Biopsy evidence is compelling but based on small patient numbers and early cohorts; durability and safety signals may still face variability as dosing expands.
Key entities
- companyPrecision BioSciences, Inc.
Clinical-stage in vivo gene editing company reporting Q2 2026 results and PBGENE-HBV and PBGENE-DMD updates.
- programPBGENE-HBV
In vivo gene editing program in ELIMINATE-B for chronic hepatitis B, targeting cccDNA elimination.
- clinical_trialELIMINATE-B
Global Phase 1 trial providing the biopsy and biomarker evidence described in the filing.
- programPBGENE-DMD
In vivo gene excision program for Duchenne muscular dystrophy, advancing the FUNCTION-DMD trial.
- clinical_trialFUNCTION-DMD
Phase 1/2 trial recruiting patients ages 2 to 7 at active sites described in the filing.